Dr. Mary Walton
In late 2019, SARS-CoV-2, the respiratory virus that caused the 2019 coronavirus disease (COVID-19), took the world by storm. The initial prominent symptoms of COVID-19 were respiratory by nature, causing widespread complications due to acute respiratory distress syndrome. In the months and years since the COVID-19 outbreak, similarity appears between the processes of COVID-19 respiratory symptoms and symptoms caused by exacerbations of reactive airway disease. Many treatment modalities have been utilized for COVID-19 related respiratory symptoms, with short-acting beta agonist use providing symptom relief in inpatient populations; however, these treatments have been slow to gain traction in outpatient management. Here the pathology of the COVID-19 virus is discussed with a recommendation for utilizing short-acting beta agonist medications to treat mild-moderate COVID-19 symptoms in the outpatient setting.
Cooper S. Short- Acting Beta Agonist Treatments in Outpatient COVID Management. Lynchburg Journal of Medical Science. 2023; 5(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.